

## anticonvulsant step therapy

### Products Affected

- APTIOM TABLET 200 MG ORAL
- APTIOM TABLET 400 MG ORAL
- APTIOM TABLET 600 MG ORAL
- APTIOM TABLET 800 MG ORAL
- BRIVIACT SOLUTION 10 MG/ML ORAL
- BRIVIACT TABLET 10 MG ORAL
- BRIVIACT TABLET 100 MG ORAL
- BRIVIACT TABLET 25 MG ORAL
- BRIVIACT TABLET 50 MG ORAL
- BRIVIACT TABLET 75 MG ORAL
- FYCOMPA SUSPENSION 0.5 MG/ML ORAL
- FYCOMPA TABLET 10 MG ORAL
- FYCOMPA TABLET 12 MG ORAL
- FYCOMPA TABLET 2 MG ORAL
- FYCOMPA TABLET 4 MG ORAL
- FYCOMPA TABLET 6 MG ORAL
- FYCOMPA TABLET 8 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL
- VIMPAT SOLUTION 10 MG/ML ORAL
- VIMPAT TABLET 100 MG ORAL
- VIMPAT TABLET 150 MG ORAL
- VIMPAT TABLET 200 MG ORAL
- VIMPAT TABLET 50 MG ORAL
- *xcopri (250 mg daily dose) tablet therapy pack 50 & 200 mg oral*
- *xcopri (350 mg daily dose) tablet therapy pack 150 & 200 mg oral*
- *xcopri tablet 100 mg oral*
- *xcopri tablet 150 mg oral*
- *xcopri tablet 200 mg oral*
- *xcopri tablet 50 mg oral*
- *xcopri tablet therapy pack 14 x 12.5 mg & 14 x 25 mg oral*
- *xcopri tablet therapy pack 14 x 150 mg & 14 x 200 mg oral*
- *xcopri tablet therapy pack 14 x 50 mg & 14 x 100 mg oral*

### Details

<b>Criteria</b>	<p>Step 1: First line therapy should be a documented trial of two of the following formulary medications: carbamazepine, carbamazepine ER, divalproex sodium, divalproex sodium ER, gabapentin, lamotrigine, lamotrigine ER, levetiracetam, levetiracetam ER, oxcarbazepine, valproic acid, zonisamide, phenytoin, phenytoin ER, felbamate, ethosuxamide, topiramate, primidone, Dilantin, phenobarbital, Phenytek or tiagabine.</p> <p>Step 2: Once two of the medications listed in Step 1 have been tried, patients can receive therapy with Aptiom, Spritam, Fycompa, Briviact, Vimpat or Xcopri.</p>
-----------------	---

# antidepressant step therapy

---

## Products Affected

- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL
- TRINTELLIX TABLET 10 MG ORAL
- TRINTELLIX TABLET 20 MG ORAL
- TRINTELLIX TABLET 5 MG ORAL
- VIIBRYD STARTER PACK KIT 10 & 20 MG ORAL
- VIIBRYD TABLET 10 MG ORAL
- VIIBRYD TABLET 20 MG ORAL
- VIIBRYD TABLET 40 MG ORAL

## Details

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of two of the following formulary medications: citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, venlafaxine ER or desvenlafaxine ER. Step 2: Once two of the medications listed in step 1 have been tried, patient can receive therapy with Trintellix, Fetzima or Viibryd.
-----------------	---

2020 3 Tier MMP-Partners  
Document: 2020 Step Therapy Criteria  
Formulary ID: 20522  
Last Updated: 11/2020  
Effective Date: 12-01-2020

## azopt step therapy

---

### Products Affected

- AZOPT SUSPENSION 1 %  
OPHTHALMIC

### Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary dorzolamide or dorzolamide/timolol. Step 2: Once dorzolamide or dorzolamide/timolol has been tried, the patient can receive therapy with Azopt.
-----------------	--

---

# combivent step therapy

---

## Products Affected

- COMBIVENT RESPIMAT AEROSOL SOLUTION 20-100 MCG/ACT INHALATION

## Details

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary Anoro Ellipta. Step 2: Once Anoro Ellipta has been tried, patients can receive therapy with Combivent Respimat.
-----------------	--

2020 3 Tier MMP-Partners  
Document: 2020 Step Therapy Criteria  
Formulary ID: 20522  
Last Updated: 11/2020  
Effective Date: 12-01-2020

## febuxostat step therapy

---

### Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

### Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary allopurinol tablet. Step 2: Once allopurinol tablet has been tried, patients can receive therapy with Febuxostat.
-----------------	--

---

# kristalose step therapy

---

## Products Affected

- KRISTALOSE PACKET 20 GM ORAL
- *lactulose packet 10 gm oral*

## Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary Constulose or lactulose. Step 2: Once Constulose or lactulose has been tried, patients can receive therapy with Kristalose or lactulose packet.
-----------------	--

2020 3 Tier MMP-Partners  
Document: 2020 Step Therapy Criteria  
Formulary ID: 20522  
Last Updated: 11/2020  
Effective Date: 12-01-2020

## ongentys step therapy

---

### Products Affected

- ONGENTYS CAPSULE 50 MG ORAL

### Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary entacapone or carbidopa-levodopa-entacapone. Step 2: Once entacapone or carbidopa-levodopa-entacapone has been tried, patients can receive therapy with Ongentys.
-----------------	--

---

# ranolazine step therapy

---

## Products Affected

- *ranolazine er tablet extended release 12 hour 1000 mg oral*
- *ranolazine er tablet extended release 12 hour 500 mg oral*

## Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of a formulary beta blocker or a calcium channel blocker. Step 2: Once a beta blocker or a calcium channel blocker has been tried, patients may receive therapy with ranolazine.
-----------------	--

---



## topical immunomodulators step therapy

---

### Products Affected

- *pimecrolimus cream 1 % external*
- *tacrolimus ointment 0.1 % external*
- *tacrolimus ointment 0.03 % external*

### Details

---

Criteria	Step 1: First line therapy should be a documented trial of two formulary topical corticosteroids. Step 2: Once two topical corticosteroids have been tried, patients can receive therapy with generic pimecrolimus or generic topical tacrolimus.
----------	---

---

# trexall step therapy

---

## Products Affected

- TREXALL TABLET 10 MG ORAL
- TREXALL TABLET 15 MG ORAL
- TREXALL TABLET 5 MG ORAL
- TREXALL TABLET 7.5 MG ORAL

## Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial with formulary generic methotrexate. Step 2: Once generic methotrexate has been tried, patients can receive Trexall.
-----------------	--

---

## urinary incontinence agents step therapy

---

### Products Affected

- *darifenacin hydrobromide er tablet extended release 24 hour 15 mg oral*
- *darifenacin hydrobromide er tablet extended release 24 hour 7.5 mg oral*
- MYRBETRIQ TABLET EXTENDED RELEASE 24 HOUR 25 MG ORAL
- MYRBETRIQ TABLET EXTENDED RELEASE 24 HOUR 50 MG ORAL
- *trospium chloride er capsule extended release 24 hour 60 mg oral*
- *trospium chloride tablet 20 mg oral*

### Details

---

Criteria	
	Step 1: First line therapy should be a documented trial of formulary oxybutynin, oxybutynin ER, tolterodine or tolterodine ER. Step 2: Second line therapy should be formulary trospium, trospium ER or darifenacin ER. Step 3: Once oxybutynin, oxybutynin ER, tolterodine or tolterodine ER AND trospium, trospium ER OR darifenacin ER have been tried, patients can receive therapy with Myrbetriq.

---

# **zafirlukast step therapy**

---

## **Products Affected**

- *zafirlukast tablet 10 mg oral*
- *zafirlukast tablet 20 mg oral*

## **Details**

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary montelukast. Step 2: Once montelukast has been tried, patients may receive therapy with zafirlukast.
-----------------	---

---

2020 3 Tier MMP-Partners  
Document: 2020 Step Therapy Criteria  
Formulary ID: 20522  
Last Updated: 11/2020  
Effective Date: 12-01-2020

## **zirgan step therapy**

---

### **Products Affected**

- ZIRGAN GEL 0.15 % OPHTHALMIC

### **Details**

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary generic trifluridine ophthalmic. Step 2: Once generic trifluridine ophthalmic has been tried, patients can receive therapy with Zirgan.
-----------------	--

---

## Index

### A

APTIOM TABLET 200 MG ORAL..... 1  
APTIOM TABLET 400 MG ORAL..... 1  
APTIOM TABLET 600 MG ORAL..... 1  
APTIOM TABLET 800 MG ORAL..... 1  
AZOPT SUSPENSION 1 %  
    OPHTHALMIC ..... 3

### B

BRIVIACT SOLUTION 10 MG/ML ORAL  
..... 1  
BRIVIACT TABLET 10 MG ORAL..... 1  
BRIVIACT TABLET 100 MG ORAL ..... 1  
BRIVIACT TABLET 25 MG ORAL ..... 1  
BRIVIACT TABLET 50 MG ORAL ..... 1  
BRIVIACT TABLET 75 MG ORAL ..... 1

### C

COMBIVENT RESPIMAT AEROSOL  
    SOLUTION 20-100 MCG/ACT  
    INHALATION..... 4

### D

darifenacin hydrobromide er tablet extended  
    release 24 hour 15 mg oral..... 11  
darifenacin hydrobromide er tablet extended  
    release 24 hour 7.5 mg oral..... 11

### F

febuxostat tablet 40 mg oral..... 5  
febuxostat tablet 80 mg oral..... 5  
FETZIMA CAPSULE EXTENDED  
    RELEASE 24 HOUR 120 MG ORAL ... 2  
FETZIMA CAPSULE EXTENDED  
    RELEASE 24 HOUR 20 MG ORAL ..... 2  
FETZIMA CAPSULE EXTENDED  
    RELEASE 24 HOUR 40 MG ORAL ..... 2  
FETZIMA CAPSULE EXTENDED  
    RELEASE 24 HOUR 80 MG ORAL ..... 2  
FETZIMA TITRATION CAPSULE ER 24  
    HOUR THERAPY PACK 20 & 40 MG  
    ORAL..... 2  
FYCOMPA SUSPENSION 0.5 MG/ML  
    ORAL..... 1  
FYCOMPA TABLET 10 MG ORAL..... 1  
FYCOMPA TABLET 12 MG ORAL..... 1  
FYCOMPA TABLET 2 MG ORAL..... 1  
FYCOMPA TABLET 4 MG ORAL..... 1  
FYCOMPA TABLET 6 MG ORAL..... 1

FYCOMPA TABLET 8 MG ORAL..... 1

### K

KRISTALOSE PACKET 20 GM ORAL ... 6

### L

lactulose packet 10 gm oral..... 6

### M

MYRBETRIQ TABLET EXTENDED  
    RELEASE 24 HOUR 25 MG ORAL ... 11  
MYRBETRIQ TABLET EXTENDED  
    RELEASE 24 HOUR 50 MG ORAL ... 11

### O

ONGENTYS CAPSULE 50 MG ORAL.... 7

### P

pimecrolimus cream 1 % external..... 9

### R

ranolazine er tablet extended release 12 hour  
    1000 mg oral ..... 8  
ranolazine er tablet extended release 12 hour  
    500 mg oral ..... 8

### S

SPRITAM TABLET DISINTEGRATING  
    SOLUBLE 1000 MG ORAL ..... 1  
SPRITAM TABLET DISINTEGRATING  
    SOLUBLE 250 MG ORAL ..... 1  
SPRITAM TABLET DISINTEGRATING  
    SOLUBLE 500 MG ORAL ..... 1  
SPRITAM TABLET DISINTEGRATING  
    SOLUBLE 750 MG ORAL ..... 1

### T

tacrolimus ointment 0.03 % external ..... 9  
tacrolimus ointment 0.1 % external ..... 9  
TREXALL TABLET 10 MG ORAL..... 10  
TREXALL TABLET 15 MG ORAL..... 10  
TREXALL TABLET 5 MG ORAL..... 10  
TREXALL TABLET 7.5 MG ORAL..... 10  
TRINTELLIX TABLET 10 MG ORAL.... 2  
TRINTELLIX TABLET 20 MG ORAL.... 2  
TRINTELLIX TABLET 5 MG ORAL..... 2  
trospium chloride er capsule extended  
    release 24 hour 60 mg oral..... 11  
trospium chloride tablet 20 mg oral..... 11

### V

VIIBRYD STARTER PACK KIT 10 & 20  
    MG ORAL ..... 2  
VIIBRYD TABLET 10 MG ORAL ..... 2

2020 3 Tier MMP-Partners  
 Document: 2020 Step Therapy Criteria  
 Formulary ID: 20522  
 Last Updated: 11/2020  
 Effective Date: 12-01-2020

VIIBRYD TABLET 20 MG ORAL ..... 2  
 VIIBRYD TABLET 40 MG ORAL ..... 2  
 VIMPAT SOLUTION 10 MG/ML ORAL. 1  
 VIMPAT TABLET 100 MG ORAL..... 1  
 VIMPAT TABLET 150 MG ORAL..... 1  
 VIMPAT TABLET 200 MG ORAL..... 1  
 VIMPAT TABLET 50 MG ORAL..... 1

**X**

xcopri (250 mg daily dose) tablet therapy  
 pack 50 & 200 mg oral..... 1  
 xcopri (350 mg daily dose) tablet therapy  
 pack 150 & 200 mg oral..... 1  
 xcopri tablet 100 mg oral ..... 1

xcopri tablet 150 mg oral ..... 1  
 xcopri tablet 200 mg oral ..... 1  
 xcopri tablet 50 mg oral ..... 1  
 xcopri tablet therapy pack 14 x 12.5 mg &  
 14 x 25 mg oral ..... 1  
 xcopri tablet therapy pack 14 x 150 mg & 14  
 x200 mg oral ..... 1  
 xcopri tablet therapy pack 14 x 50 mg & 14  
 x100 mg oral ..... 1

**Z**

zafirlukast tablet 10 mg oral ..... 12  
 zafirlukast tablet 20 mg oral ..... 12  
 ZIRGAN GEL 0.15 % OPHTHALMIC ... 13